- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners
Latest from UCLA Health Jonsson Comprehensive Cancer Center
Dr. Wainberg on the Potential Role of Neoadjuvant Chemotherapy in Pancreatic Cancer
April 01, 2021
Video
Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.
As FDA Review Approaches, Finn Reflects on the Utility of Pembrolizumab, Nivolumab in HCC
March 17, 2021
Article
Richard S. Finn, MD, discusses the data with pembrolizumab and nivolumab that support their utility in hepatocellular carcinoma.
Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL
March 12, 2021
Video
Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.
New HER2-Targeting Therapies Jostle for a Place in the Treatment Lineup
March 06, 2021
Article
The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.
Dr. Mead on the Utility of Second-Line Venetoclax/Rituximab in CLL
March 05, 2021
Video
Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.